Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects

Fig. 1

AMG 403 concentration-time profiles following single and repeat dose administration. AMG 403 was administered intravenously (IV) or subcutaneously (SC) and serum AMG 403 levels were measured pre-dose through end of study. Each point represents the mean (+SD) AMG 403 concentration. a Healthy volunteers received a single IV or SC dose of AMG 403 (1–30 mg, LLOQ = 0.0016 μg/mL). b Patients with knee osteoarthritis received a once-monthly SC dose of AMG 403 (3–20 mg, LLOQ = 0.0051 μg/mL) for up to four dose administrations. Arrows represent dose administration

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us